Published in J Clin Oncol on September 01, 2004
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35
Breast cancer metastasis to the central nervous system. Am J Pathol (2005) 3.30
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer (2007) 3.06
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Prognostic factors affecting the outcome of brain metastases from breast cancer. Support Care Cancer (2006) 2.17
Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res (2008) 1.95
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res (2011) 1.46
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol (2013) 1.45
Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A (2009) 1.45
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A (2011) 1.41
Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun (2017) 1.39
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res (2009) 1.36
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer (2009) 1.30
Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer (2009) 1.26
Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health (2012) 1.26
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol (2014) 1.22
Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res (2011) 1.18
Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis (2008) 1.14
Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res (2013) 1.10
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res (2013) 1.02
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res (2015) 1.01
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer (2012) 1.00
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer (2007) 0.97
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer (2011) 0.96
Survival following gamma knife radiosurgery for brain metastasis from breast cancer. Radiat Oncol (2013) 0.96
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res (2011) 0.95
Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model. PLoS One (2013) 0.95
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res (2012) 0.95
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res (2011) 0.93
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol (2009) 0.93
Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist (2013) 0.93
Unsuspected breast carcinoma presenting as orbital complication of rhinosinusitis. Eur Arch Otorhinolaryngol (2007) 0.93
Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res (2016) 0.92
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer (2015) 0.92
A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol (2011) 0.91
Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med (2015) 0.90
Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget (2014) 0.89
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One (2013) 0.89
A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer (2011) 0.89
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother (2011) 0.89
Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis (2013) 0.88
In Vivo Magnetic Resonance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases due to Breast Cancer. Transl Oncol (2012) 0.88
DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J Natl Cancer Inst (2014) 0.87
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer (2012) 0.87
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol (2015) 0.87
Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol (2013) 0.87
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One (2010) 0.86
Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. BMC Cancer (2015) 0.86
Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles. ScientificWorldJournal (2012) 0.85
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2014) 0.85
Molecular interactions in the development of brain metastases. Int J Mol Sci (2013) 0.85
Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. Springerplus (2013) 0.85
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist (2010) 0.85
Emerging role of brain metastases in the prognosis of breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.84
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist (2015) 0.84
An institutional retrospective analysis of 93 patients with brain metastases from breast cancer: treatment outcomes, diagnosis-specific prognostic factors. Int J Mol Sci (2012) 0.83
Longitudinal MRI evaluation of intracranial development and vascular characteristics of breast cancer brain metastases in a mouse model. PLoS One (2013) 0.83
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol (2013) 0.83
Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene (2015) 0.82
Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models. Breast Cancer Res Treat (2014) 0.82
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget (2015) 0.82
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat (2012) 0.82
Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One (2014) 0.82
Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro Oncol (2016) 0.81
Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press) (2010) 0.81
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol (2016) 0.81
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer. Oncotarget (2016) 0.80
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer (2010) 0.80
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol (2015) 0.80
Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain (2015) 0.80
Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J (2017) 0.80
Molecular aspects of breast cancer metastasis to the brain. Genet Res Int (2011) 0.79
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget (2015) 0.79
The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Contemp Oncol (Pozn) (2013) 0.79
Nasal cavity metastasis of breast cancer: a case report and review of the literature. Int J Clin Exp Pathol (2014) 0.79
Breast cancer metastasis and the lymphatic system. Oncol Lett (2015) 0.79
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.79
Low Expression of Slit2 and Robo1 is Associated with Poor Prognosis and Brain-specific Metastasis of Breast Cancer Patients. Sci Rep (2015) 0.78
Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively. Cancer Res (2014) 0.78
The shifting landscape of metastatic breast cancer to the CNS. Neurosurg Rev (2012) 0.78
Gene Expression Profiling of Breast Cancer Brain Metastasis. Sci Rep (2016) 0.78
Quality of life and symptom burden in patients with metastatic breast cancer. Support Care Cancer (2016) 0.78
Management of solitary and multiple brain metastases from breast cancer. Indian J Med Paediatr Oncol (2015) 0.77
Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports. J Breast Cancer (2016) 0.77
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Informing clinical trial participants about study results. JAMA (2002) 3.76
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol (2008) 3.04
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol (2008) 2.72
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) (2012) 2.50
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35
Do patients participating in clinical trials want to know study results? J Natl Cancer Inst (2003) 2.33
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol (2011) 2.30
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst (2010) 2.28
Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol (2006) 2.24
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol (2008) 2.04
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol (2007) 1.77
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol (2008) 1.69
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol (2012) 1.62
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat (2003) 1.60
Complementary and alternative medicine use among women with breast cancer. J Clin Oncol (2002) 1.60
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res (2010) 1.56
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care (2009) 1.51
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst (2004) 1.51
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer (2007) 1.47
Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer (2008) 1.45
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol (2015) 1.43
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat (2012) 1.43
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol (2002) 1.42
Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int J Radiat Oncol Biol Phys (2007) 1.37
Body image in recently diagnosed young women with early breast cancer. Psychooncology (2012) 1.36
The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med (2005) 1.35
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat (2008) 1.32
Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol (2003) 1.31
Evidence for multiple interspecific hybridization in Saccharomyces sensu stricto species. FEMS Yeast Res (2002) 1.29
Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol (2008) 1.28
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res (2008) 1.27
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast (2013) 1.23
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Sharing study results with trial participants: time for action. J Clin Oncol (2009) 1.22
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol (2007) 1.19
On mammography--more agreement than disagreement. N Engl J Med (2009) 1.17
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol (2011) 1.17
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
The effect of age on delay in diagnosis and stage of breast cancer. Oncologist (2012) 1.15
Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer (2008) 1.13
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat (2008) 1.12
Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Res Treat (2009) 1.11
The ethical use of mandatory research biopsies. Nat Rev Clin Oncol (2011) 1.11
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol (2004) 1.10